Edesa Biotech Stock (NASDAQ:EDSA)
Previous Close
$2.40
52W Range
$1.55 - $5.45
50D Avg
$2.07
200D Avg
$2.31
Market Cap
$16.71M
Avg Vol (3M)
$27.66K
Beta
0.40
Div Yield
-
EDSA Company Profile
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNOA | Sonoma Pharmaceuticals, Inc. |
| HOTH | Hoth Therapeutics, Inc. |
| SNTI | Senti Biosciences, Inc. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| VRPX | Virpax Pharmaceuticals, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| IMRN | Immuron Limited |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| PSTV | Plus Therapeutics, Inc. |